Power Clinical Decisions in Gynecologic Cancer
ctDNA presence after surgery is associated with reduced recurrence-free survival
clinical sensitivity and specificity1 during longitudinal testing for patients with stage I-IV epithelial ovarian cancer (EOC)*
Detect Recurrence Earlier
Signatera™ is a stronger predictor of recurrence than CA-125
average lead time over CT scans in patients with EOC, compared to 1 month for CA-1251
Monitor Treatment Response
Serial Signatera™ testing during immunotherapy can help assess therapy effectiveness
evaluate immune checkpoint inhibitor
response early for patients with
Understand Immunotherapy Response Earlier
Inform clinical decisions by tracking ctDNA dynamics
The Signatera™ Residual Disease Test can be used to monitor immunotherapy response and identify treatment effectiveness as early as week 6 in ovarian, cervical, endometrial, and other cancers.2
Actionable Molecular Insights Across the Patient Journey
Signatera™ enables early detection of molecular residual disease (MRD) to help you manage your patients with gynecologic cancers.
Discover the Data in Gynecologic Cancers
- Signatera™ is clinically validated cross multiple indications.
Monitor Your Patients With Confidence
As part of her ovarian cancer monitoring plan, Anne received Signatera™ testing and CA-125 at regular intervals.
A positive Signatera™ result alerted her oncologist to order a scan, which caught a recurrence early. Now, Anne is receiving Signatera™ to monitor response to her maintenance therapy. Since starting therapy, Anne’s Signatera™ results have been negative, so she can feel more confident about her treatment plan.
Tailor Gynecologic Cancer Treatment With Natera’s Portfolio of Genomic Tests
|Signatera™||Highly sensitive and perosnalized tumor-informed test for molecular residual disease (MRD) detection|
|Altera™||Comprehensive genomic profiling for clinically relevant somatic mutations/biomarkers with no additional sample (eg NTRK fusions, MSI, TMB, BRCA 1/2)|
|Empower™||Germline genetic test for commonly screened genes in gynecologic cancers (eg BRCA 1/2, MMR genes) to inform therapeutic decisions.|
More Clinician Resources
Signatera™ in Gynecologic Cancers
Read about the clinical utility of the Signatera™ test and data for MRD assessment, recurrence monitoring, and IO treatment response monitoring.
IO Monitoring Brochure
Learn how Signatera™ can assess immunotherapy response as early as 6 weeks into treatment for patients with ovarian, cervical, endometrial, and other cancers.2
Ready to try Signatera™ for your gynecologic cancer patients?
1Chapman J, et al. Circulating tumor DNA predicts disease recurrence in ovarian cancer patients. Poster presented at the American Association of Cancer Research annual meeting; April 10-15, 2021; Virtual Meeting. Abstract 552.
2Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1(9):873-881. https://doi.org/10.1038/s43018-020-0096-5
*Includes epithelial ovarian, fallopian tube, and peritoneal cancer. Median follow-up period of 15 months (n=25)
**Includes high grade serous ovarian cancer (n=18), endometrial cancer (n=2), and cervical cancer (n=1).